Binaytara Foundation Hosts the 2023 Global Oncology Summit in Bellevue, WA

Bellevue, WA – October 24, 2024
The Binaytara Foundation, a leading global cancer non-profit organization dedicated to improving access to cancer care, is set to host its annual Global Oncology Summit on October 28, 2023.
This year’s summit, drawing experts and professionals from around the globe, is slated to be one of the most significant gatherings of global oncology minds. It is expected to address the evolving challenges and breakthroughs in the field of global oncology. The 2023 Global Oncology Summit promises an engaging agenda, with keynote addresses and panel discussions. Topics will range from infrastructure development to sustainability in resource-limited settings. 

Founded by Dr. Binay Shah and Mrs Tara Shah, the Binaytara Foundation has consistently championed the cause of accessible and advanced cancer care.

“Our aim has always been to ensure that everyone, regardless of their circumstances, has the right to world-class cancer care,” remarked Dr. Shah. “By hosting this summit, we hope to further that mission by fostering dialogue, collaboration, and innovation.”

 

Ensuring accessibility for all, the foundation has also facilitated a virtual participation option. This hybrid model aims to be more inclusive and accommodating to the global oncology community. With leading experts, thought-provoking discussions, and a commitment to bettering global oncology practices, the 2023 Global Oncology Summit sets the tone for the future of global oncology discussions.

For those interested in attending or accessing conference proceedings, registration details and additional information are available here: https://education.binayfoundation.org/content/2023-global-oncology-summit-focus-sustainability.
Tara Shah

Recent Posts

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central…

6 months ago

ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng21. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred…

6 months ago

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug…

7 months ago